MedTrace Logo

Evaluate the Diagnostic Efficacy, Pharmacokinetics and Safety of 68Ga-DOTATATE Injection PET/CT in NETs

NCT07119242 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2025-08-13

No results posted yet for this study

Summary

Evaluate the diagnostic efficacy, pharmacokinetics and safety of 68Ga-DOTATATE injection PET/CT in NETs

Conditions

  • NETs

Interventions

DRUG

68Ga-DOTATATE Injection

The eligible subjects who participate in 68Ga study will be intravenously injected with 68Ga-DOTATATE Injection on Day1，and undergo PET/CT examination within 60 minutes after injection. Corresponding safety examination is performed before administration of 68Ga-DOTATATE Injection, 3h±1.0h after administration, and Day2. Telephone safety visit is conducted at Day7 after administration.

Sponsors & Collaborators

  • HTA Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DIAGNOSTIC
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-08
Primary Completion
2024-11-11
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07119242 on ClinicalTrials.gov